The accelerated review of its hepatitis B treatment is another shot in the arm for GSK following strong results last month which saw it upgrade forecasts.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.